Business News • PR NewsWire • The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals' results of the phase IIb study with cobitolimod

The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals' results of the phase IIb study with cobitolimod

The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals' results of the phase IIb study with cobitolimod

STOCKHOLM, Oct. 6, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology. CONDUCT was a phase IIb dose optimisation study,...

View More : https://www.prnewswire.com:443/news-releases/the-lancet-gastroenterology-and-hepatology-publishes-index-pharmaceuticals-...

Releted News by prnewswire

Tobii divests Smartbox

Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology

The Global Liquefied Petroleum Gas (LPG) Cylinder Market is expected to grow by USD 407.60 mn during 2020-2024, progressing at a CAGR of 4% during the forecast period

From the Tax Law Offices of David W. Klasing - When should you consider appealing an IRS audit assessment and what is involved?